Brenntag acquires Brazilian specialty chemical distributors PIC and PharmaSpecial

Brenntag, a global market leader in chemical and ingredient distribution, announces the acquisition of PIC Química e Farmacêutica Ltda. (PIC) and PharmaSpecial Especialidades Químicas e Farmacêuticas Ltda. in Brazil. The acquisition significantly enhances the company’s position in the growing Life Science market in Brazil. PIC and PharmaSpecial are well-known, family-owned specialty chemical distributors serving key accounts and national compounding pharmacies in the pharmaceutical, personal care and other life science industries.

Torsten Walz, Global President of Brenntag Specialties’ Pharmaceutical Business, commented: “PIC and PharmaSpecial have built a broad portfolio of world-class suppliers and value-added services that are highly compatible with our global pharmaceutical strategy. I look forward to building on this and expanding our presence in the region.”

The acquisition in Latin America by Brenntag Specialties is also an opportunity for Brenntag to expand its global network of Application & Innovation Centers. In addition, the company enters the softgel capsule market.

François Bleger, Global President Beauty & Care at Brenntag Specialties, added: "I wholeheartedly welcome and look forward to working with our new colleagues. This transaction is an important step forward in our goal to expand our presence in Latin America, better serve our customers and broaden our value-added service capabilities."

"Joining Brenntag is a great opportunity to grow our business," commented Fabio Morais, CEO of PIC and PharmaSpecial. "Our dedicated team will be able to better serve our regional customers with the global expertise and network of Application & Innovation Centers that Brenntag offers. This gives our supply partners a broad global reach. I am very much looking forward to seeing what the future holds."

Founded in 1991 and headquartered in Itapevi, Brazil, the two companies had sales of approximately €11 million in 2023. Financial details of the transaction were not disclosed. Closing of the transaction is subject to customary conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2024.